8-K: NewAmsterdam Pharma Announces Positive Phase 3 Trial Results for Obicetrapib in Cholesterol Treatment

NewAmsterdam Pharma's Phase 3 BROOKLYN trial demonstrated significant LDL-C reduction with obicetrapib in patients with heterozygous familial hypercholesterolemia.

Summary

• NewAmsterdam Pharma announced positive topline results from its Phase 3 BROOKLYN clinical trial.
• The trial evaluated obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C was not adequately controlled despite being on maximally tolerated lipid-lowering therapy.
• The study met its primary endpoint, showing a statistically significant reduction in LDL-C at day 84 compared to placebo.
• The LDL-C reduction was sustained at day 365.
• Obicetrapib achieved a 36.3% reduction in LDL-C at day 84 and a 41.5% reduction at day 365 compared to placebo.
• 51% of patients in the obicetrapib arm achieved an LDL-C level below 70 mg/dl.
• The trial included 354 patients randomized 2:1 to receive 10 mg obicetrapib or placebo.
• The mean baseline LDL-C for patients in the obicetrapib arm was 123 mg/dL.
• Approximately 79% of patients were on high-intensity statin therapy during screening.
• Obicetrapib was generally well-tolerated, with safety results comparable to placebo.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with significant LDL-C reduction and a good safety profile. The management commentary is also very positive, indicating high confidence in the drug's potential. The only minor negative is the slightly higher discontinuation rate in the placebo group, but this is not a major concern.

Positives

• Obicetrapib demonstrated a significant and sustained reduction in LDL-C levels.
• The drug was well-tolerated with a safety profile similar to placebo.
• A substantial proportion of patients achieved target LDL-C levels.
• The results support obicetrapib as a potential new oral treatment option for HeFH patients.
• The study met several of its prespecified secondary endpoints with statistical significance.

Negatives

• The treatment discontinuation rate was higher in the placebo group at 14.4% compared to 7.6% in the obicetrapib group, which could indicate some tolerability issues with the placebo.
• There were some treatment emergent adverse events, although they were comparable to placebo.

Risks

• The company faces risks related to regulatory approval of obicetrapib.
• There are risks associated with commercializing the product candidate.
• The company faces competition from other product candidates.
• There are risks related to the company's ability to negotiate and enter into definitive agreements on favorable terms.
• The company faces risks related to intellectual property claims.
• The company faces risks related to attracting and retaining qualified personnel.
• The company faces risks related to sourcing raw materials for its product candidate.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, could impact the company's business.

Future Outlook

The company anticipates multiple potential pivotal data readouts in the next 12 months, including topline data from the BROADWAY trial expected in the fourth quarter of 2024 and topline data from the TANDEM trial expected in the first quarter of 2025. The company also plans to present full results from BROOKLYN at an upcoming medical conference and to publish the data in a major medical journal.

Management Comments

• John Kastelein, Chief Scientific Officer, stated that many patients with familial hypercholesterolemia have exhausted available treatment options and expressed delight with the topline data from BROOKLYN.
• Michael Davidson, Chief Executive Officer, noted that despite the widespread availability of lipid-lowering therapies, CVD-related deaths have risen and patients remain above LDL-C targets, emphasizing the need for additional options.
• Stephen Nicholls, Director, Monash Victorian Heart Institute, expressed encouragement by the results, suggesting that obicetrapib, if approved, has the potential to be a new oral option for a difficult-to-treat patient population.
• Katherine Wilemon, Founder and CEO of the Family Heart Foundation, stated that familial hypercholesterolemia often requires multiple therapies and expressed encouragement with the potential to have another efficacious oral option.

Industry Context

This announcement is significant as it addresses the unmet need for effective LDL-C lowering therapies in patients with HeFH, a population that often struggles to reach target levels despite existing treatments. The positive results from the BROOKLYN trial position obicetrapib as a potential competitor in the lipid-lowering market, particularly for patients who require additional options beyond statins and other current therapies.

Comparison to Industry Standards

• The LDL-C reduction achieved by obicetrapib in the BROOKLYN trial is comparable to or better than some existing non-statin therapies.
• For example, PCSK9 inhibitors like evolocumab and alirocumab have shown significant LDL-C reductions, but they are injectable and not oral like obicetrapib.
• Ezetimibe, another non-statin oral therapy, typically provides more modest LDL-C reductions compared to what was observed with obicetrapib.
• The results suggest that obicetrapib could potentially fill a gap in the market for a potent oral LDL-C lowering agent, especially for patients who cannot tolerate or do not respond adequately to other therapies.
• The safety profile of obicetrapib, being comparable to placebo, is also a positive differentiator compared to some other lipid-lowering drugs that may have more significant side effects.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with HeFH may benefit from a new, effective oral treatment option.
• Physicians will have another tool to manage patients with high LDL-C.
• The company's employees may be motivated by the positive results and the potential for commercial success.
• The company's suppliers may see increased demand for raw materials.

Next Steps

• The company plans to present full results from BROOKLYN at an upcoming medical conference.
• The company plans to publish the data in a major medical journal.
• The company will continue with its ongoing Phase 3 trials, BROADWAY and TANDEM.
• The company will continue to monitor the PREVAIL cardiovascular outcomes trial.

Key Dates

Keywords

Obicetrapib, Heterozygous Familial Hypercholesterolemia, HeFH, LDL-C, Cholesterol, Cardiovascular Disease, Lipid-lowering therapy, Clinical Trial, Phase 3, NewAmsterdam Pharma